Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr−/− mice  Sabrina Noël, Pierre-Olivier Strale, Luc Dannhoffer, Martina.

Slides:



Advertisements
Similar presentations
J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Advertisements

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice 
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham 
CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype  Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function  Fredrick Van Goor, Haihui Yu, Bill.
Effect of VX-770 (Ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells  Laura Vachel, Caroline Norez, Frédéric.
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis?  Darren Shepherd, Yvonne Belessis,
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis  Marco Zampoli, Komala Pillay, Henri Carrara,
Cirrhosis and other liver disease in cystic fibrosis
Curcumin and genistein additively potentiate G551D-CFTR
Johanna F. Dekkers, Peter Van Mourik, Annelotte M
Controlled clinical trials in cystic fibrosis — are we doing better?
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar 
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
Influence of digital clubbing on oxygen saturation measurements by pulse-oximetry in cystic fibrosis patients  Filip Van Ginderdeuren, Karlien Van Cauwelaert,
Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial  S.K. Kabra, R. Pawaiya, Rakesh Lodha,
Clinical presentation of mild cystic fibrosis in a Serbian patient homozygous for the CFTR mutation c G>A  Aleksandra Nikolic, Nedeljko Radlovic,
Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis  Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,
Spontaneous coronary artery dissection associated with coughing
A.H. Gifford  Journal of Cystic Fibrosis 
M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade 
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Inhalation solutions — Which ones may be mixed
Physiologic endpoints for clinical studies for cystic fibrosis
Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C
Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India  Shivaram S. Shastri, Madhulika Kabra, Sushil.
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?
Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J
Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis  Christopher R. Sudfeld, Elliott C. Dasenbrook, William.
Transepithelial fluctuation analysis of chloride secretion
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients  E.B. Wilms, D.J. Touw, H.G.M. Heijerman 
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.
R. Dekkers, L. A. W. Vijftigschild, A. M. Vonk, E. Kruisselbrink, K. M
Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire  Joän M. Patterson, Melanie Wall, Jerica.
Higher risk of hospitalization among females with cystic fibrosis
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal 
A new method of sweat testing: the CF Quantum®sweat test
Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids  Francis J. Gilchrist, A.
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation  Markus Hofer, Christoph Schmid, Christian Benden, Rudolf Speich,
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Modification of the salivary secretion assay in F508del mice — The murine equivalent of the human sweat test  Karoline Droebner, Peter Sandner  Journal.
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
L. Nshimyumukiza, A. Bois, P. Daigneault, L. Lands, A. -M. Laberge, D
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Cystic fibrosis and pregnancy in the modern era: A case control study
Presentation transcript:

Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr−/− mice  Sabrina Noël, Pierre-Olivier Strale, Luc Dannhoffer, Martina Wilke, Hugo DeJonge, Christian Rogier, Yvette Mettey, Frédéric Becq  Journal of Cystic Fibrosis  Volume 7, Issue 2, Pages 128-133 (March 2008) DOI: 10.1016/j.jcf.2007.06.005 Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Chemical structure of MPB-07 (10-chloro-6-hydroxybenzo[c]quinolizinium chloride) and MPB-05 (6-hydroxybenzo[c]quinolizinium chloride). Journal of Cystic Fibrosis 2008 7, 128-133DOI: (10.1016/j.jcf.2007.06.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Effect of MPB-07 compound on the salivary secretion of Cftr+/+ and Cftr−/− mice. Typical salivary response in the presence of isoprenaline alone or iso+MPB-07 for Cftr+/+ (A) and Cftr−/− mice (B). Average of salivary rates of secretion for Cftr+/+ and Cftr−/− mice (C). Total saliva secretion for Cftr+/+ and Cftr−/− mice (D). For these experiments, 5≤n≤6. Journal of Cystic Fibrosis 2008 7, 128-133DOI: (10.1016/j.jcf.2007.06.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Effect of genistein on the salivary secretion of Cftr+/+ mice. Salivary response in the presence of isoprenaline+ethanol 0 1% compared to isoprenaline+genistein 50 μM (A). Average of salivary rates of secretion (B). Total saliva secretion (C). For these experiments, 3≤n≤4. Journal of Cystic Fibrosis 2008 7, 128-133DOI: (10.1016/j.jcf.2007.06.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Dose-dependent effect of MPB-07 on salivary secretion of Cftr+/+ mice. (A) curves showing the rate of salivary secretion stimulated by increasing doses of MPB-07 in presence  μM isoprenaline. (B) Mean total saliva secreted during of 10stimulation by various doses of MPB-07 as indicated. For these experiments, 5≤n≤6. Journal of Cystic Fibrosis 2008 7, 128-133DOI: (10.1016/j.jcf.2007.06.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 5 Effect of MPB-05 compound on salivary secretion of Cftr+/+ mice. (A) average of salivary rate in the presence of isoprenaline alone, or combined with 500 μM of MPB-05. The dotted line indicates the effect of MPB-07 for comparison. (B) Mean value of total saliva secretion collected during the whole experiment as described in A. For these experiments, 4≤n≤6. Journal of Cystic Fibrosis 2008 7, 128-133DOI: (10.1016/j.jcf.2007.06.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions